Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02527798 · ClinicalTrials.gov registry record · Phase 2
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
A Phase 2 study of Bronchopulmonary Dysplasia, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
- 20
- Study locations
NCT02527798 is a Phase 2 study of Bronchopulmonary Dysplasia that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 82 participants, below the 233-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT02527798, a Phase 2 study of Bronchopulmonary Dysplasia, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Furosemide Cohort 1
- DRUG Furosemide Cohort 2
- DRUG Furosemide Cohort 3
Study Locations (20)
Florida
- University of Florida Jacskonville Shands Medical Center - Jacksonville
- Wolfson Children's Hospital - Jacksonville
- South Miami Hospital - South Miami
- John's Hopkins Al Children's Hospital - St. Petersburg
Massachusetts
- Floating Hospital for Children at Tufts Medical Center - Boston
- UMass Memorial Medical Center - Worcester
North Carolina
- The University of North Carolina at Chapel Hill/North Carolina Children's Hospital - Chapel Hill
- New Hanover Regional Medical Center - Wilmington
Ohio
- MetroHealth Medical Center - Cleveland
- Nationwide Children's Hospital/The Ohio State University - Columbus
Arkansas
- Arkansas Children's Hospital/University of Arkansas for Medical Sciences - Little Rock
California
- Loma Linda University Medical Center - Loma Linda
Illinois
- University of Illinois at Chicago - Chicago
Kansas
- Wesley Medical Center - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2015-11-27 |
| Est. Completion | 2019-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02527798
The ClinicalTrials.gov registry entry for NCT02527798 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 233-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target (65% lower). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02527798 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT02527798 about?
NCT02527798 is a clinical study titled "Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)". This study will describe the safety of furosemide in premature infants at risk of bronchopulmonary dysplasia and determine the preliminary effectiveness and pharmacokinetics (PK) of furosemide. Funding Source - FDA OOPD
What is the current status of trial NCT02527798?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2015-11-27. Estimated completion is 2019-10-15.
What conditions does trial NCT02527798 study?
This clinical trial studies the following conditions: Bronchopulmonary Dysplasia.
What interventions are being tested in trial NCT02527798?
The interventions under investigation include: Placebo (OTHER), Furosemide Cohort 1 (DRUG), Furosemide Cohort 2 (DRUG), Furosemide Cohort 3 (DRUG).
Who is sponsoring clinical trial NCT02527798?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02527798 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchopulmonary Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
RECRUITING · Phase 2
-
Vitamin D Supplementation for Extremely Preterm Infants
COMPLETED · Phase 2
-
Safety of Sildenafil in Premature Infants
COMPLETED · Phase 2
-
Trial II of Lung Protection With Azithromycin in the Preterm Infant
COMPLETED · Phase 2
-
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
COMPLETED · Phase 2
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.